Healthcare

• The company prioritises advancing pivotal trial design discussions with pharmaceutical collaborators, including Merck & Co..

• The company prioritises progressing US FDA investigational device exemption submissions and expanding European clinical case volumes.

• The company prioritises tracking intratumoural viral replication and the durability of systemic T-cell activation.

• The company prioritises converting clinical practice guideline endorsements into contracted software subscriptions.

• The company prioritises establishing multicentre outpatient photodynamic therapy clinics with hospital partners.

• The company prioritises engaging regulators on registrational trial designs for intracranial pressure-related disease.

• The company prioritises expanding assay distribution agreements with major US medical distributors.